Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

Dividend investing is a simple way to generate regular income. Vanguard ETFs offer a low-cost way to gain diversified income exposure with lower ri...

3 Vanguard Dividend ETFs to Boost Passive Income

Envista Holdings (($NVST)) has held its Q2 earnings call. Read on for the main highlights of the call. Envista Holdings’ latest earnings call struc...

Envista Holdings Lifts Outlook After Strong Quarter

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Envista Holdings today and set a price target of $31.00. According to TipRanks, B...

Stifel Nicolaus Sticks to Their Buy Rating for Envista Holdings (NVST)

In a report released yesterday, Vik Chopra from BMO Capital maintained a Hold rating on Envista Holdings, with a price target of $29.00. The compan...

Envista Holdings (NVST) Gets a Hold from BMO Capital

Dividend ETFs are one of the most popular ways to earn passive income, but choosing the right fund isn’t always easy. Among the leading options are...

SCHD vs. VYMI: Which Dividend ETF Comes Out on Top?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Repligen (RGEN) and Envista Holdings (NVST). Repligen (RGEN) RBC ...

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN) and Envista Holdings (NVST)

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis, with a price target of $147.00. The company...

Berenberg Bank Remains a Hold on Novartis (NVS)

Dividend ETFs can be a simple way to earn regular income while staying invested in the stock market. Vanguard offers several dividend ETFs that hol...

3 Best Vanguard ETFs to Boost Your Dividend Income

Analysts fell to the sidelines weighing in on Envista Holdings (NVST) and Molina Healthcare (MOH) with neutral ratings, indicating that the experts...

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Molina Healthcare (MOH)

WSW, NY, July 23rd, 2026, FinanceWire Nuvectis Pharma (NASDAQ:NVCT) announced this morning that ciprocopan (NXP100) has been approved by China’s Na...

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

Dividend ETFs remain a go-to choice for investors seeking steady income. Two leading choices are the Schwab U.S. Dividend Equity ETF ($SCHD) and th...

VYMI vs. SCHD: Which Is the Best Dividend ETF for Passive Income?

DZ BANK AG analyst Elmar Kraus maintained a Hold rating on Novartis AG yesterday. The company’s shares closed yesterday at CHF125.34. Kraus covers ...

Novartis AG (NOVN) Gets a Hold from DZ BANK AG

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novartis AG, with a price target of CHF135.00. According to ...

Novartis AG (NOVN) Gets a Buy from J.P. Morgan

The latest announcement is out from Novartis ( ($NVS) ). On July 21, 2026, Novartis reported second-quarter 2026 results showing a return to top-li...

Novartis Returns to Sales Growth in Q2 2026 but Earnings Weaken as Guidance Reaffirmed

Bernstein analyst Justin Smith maintained a Hold rating on Novartis AG today and set a price target of CHF125.00. According to TipRanks, Smith is a...

Novartis AG (NOVN) Receives a Hold from Bernstein

Jefferies analyst Michael Leuchten maintained a Hold rating on Novartis AG today and set a price target of CHF110.00. According to TipRanks, Leucht...

Jefferies Keeps Their Hold Rating on Novartis AG (NOVN)

Stocks ended the week lower as weakness in technology shares and disappointing corporate outlooks weighed on the major U.S. indexes. The Dow Jones ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVS	$150.88	-0.55%	1.60M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVS	$150.88	-0.6%	1.60M
3
4
5
6

NVS

Get Novartis AG Data in Excel

Get Novartis AG Data in Excel